Topiramate use in pregnancy and the birth prevalence of oral clefts

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 10, 2014, Pages 1017-1025

  Mines, Daniel ^a   Tennis, Patricia ^b   Curkendall, Suellen M ^c   Li, De Kun ^d   Peterson, Craig ^e   Andrews, Elizabeth B ^b   Calingaert, Brian ^b   Chen, Hong ^d   Deshpande, Gaurav ^a   Esposito, Daina B ^a   Everage, Nicholas ^f   Holick, Crystal N ^a   Meyer, Nicole M ^c   Nkhoma, Ella T ^a   Quinn, Sherry ^f   Rothman, Kenneth J ^b   Chan, K Arnold ^f  

^a HEALTHCORE INC   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c IBM WATSON HEALTH   (United States)

^d DIVISION OF RESEARCH   (United States)

^e Menlo Park and VIVUS   (United States)

^f OPTUM   (United States)

Author keywords

Abnormalities; Cleft lip; Cleft palate; Delayed effects; Drug induced; Oral cleft; Pharmacoepidemiology; Prenatal exposure; Topiramate

Indexed keywords

TOPIRAMATE; FRUCTOSE;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; ELECTRONIC MEDICAL RECORD; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MOUTH MALFORMATION; ORAL CLEFT; OUTCOME ASSESSMENT; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PREVALENCE; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLEFT LIP; CLEFT PALATE; FACTUAL DATABASE; NEWBORN; PREGNANCY; PRENATAL EXPOSURE; UNITED STATES;

CALIFORNIA; CLEFT LIP; CLEFT PALATE; COHORT STUDIES; DATABASES, FACTUAL; ELECTRONIC HEALTH RECORDS; FEMALE; FRUCTOSE; HUMANS; INFANT, NEWBORN; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 84911806232     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3612     Document Type: Article

References (24)

1. Letmaier M, Schreinzer D, Wolf R, Kasper S. Topiramate as a mood stabilizer. Int Clin Psychopharmacol 2001; 16: 295-298.
2. Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathic pain. Clin J Pain 2003; 19: 59-68.
3. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722-733.
4. Astrup A, Caterson I, Zelissen P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004; 12: 1658-1669.
5. Tremblay A, Chaput JP, Berube-Parent S, et al. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur J Clin Pharmacol 2007; 63: 123-134.
6. Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK epilepsy and pregnancy register. Neurology 2008; 71: 272-276.
7. Hernandez-Diaz S, Smith CR, Shen A, et al. North American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012; 78(21): 1692-1699.
8. FDA Drug Safety Communication: risk of oral clefts in children born to mothers taking Topamax (topiramate). U.S. Food and Drug Administration, 3-4-2011.
9. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16: 1075-1085.
10. Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16: 474-484.
11. Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010; 303: 1401-1409.
12. Wertz DA, Chang CL, Sarawate CA, Willey VJ, Cziraky MJ, Bohn RL. Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circ Cardiovasc Qual Outcomes 2010; 3: 538-545.
13. Boulet SL, Grosse SD, Honein MA, Correa-Villasenor A. Children with orofacial clefts: health-care use and costs among a privately insured population. Public Health Rep 2009; 124: 447-453.
14. Li DK, Yang C, Andrade S, Tavares V, Ferber JR. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011; 343: d5931.
15. Stegmann BJ, Carey JC. TORCH infections. Toxoplasmosis, other (syphilis, varicella-zoster, parvovirus B19), rubella, cytomegalovirus (CMV), and herpes infections. Curr Womens Health Rep 2002; 2: 253-258.
16. Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2007. Natl Vital Stat Rep 2010; 58: 1-85.
17. Parker SE, Mai CT, Canfield MA, et al. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Res A Clin Mol Teratol 2010; 88: 1008-1016.
18. Margulis AV, Mitchell AA, Gilboa SM, et al. National Birth Defects Prevantion Study. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012; 207(5): 405.e1-7.
19. Green MW, Seeger JD, Peterson C, Bhattacharyya A. Utilization of topiramate during pregnancy and risk of birth defects. Headache 2012; 52: 1070-1084.
20. Watkins ML, Rasmussen SA, Honein MA, Botto LD, Moore CA. Maternal obesity and risk for birth defects. Pediatrics 2003; 111: 1152-1158.
21. Little J, Cardy A, Arslan MT, Gilmour M, Mossey PA. Smoking and orofacial clefts: a United Kingdom-based case-control study. Cleft Palate Craniofac J 2004; 41: 381-386.
22. Little J, Cardy A, Munger RG. Tobacco smoking and oral clefts: a meta-analysis. Bull World Health Organ 2004; 82: 213-218.
23. Goodwin RD, Pagura J, Spiwak R, Lemeshow AR, Sareen J. Predictors of persistent nicotine dependence among adults in the United States. Drug Alcohol Depend 2011; 118: 127-133.
24. Swendsen J, Conway KP, Degenhardt L, et al. Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the National Comorbidity Survey. Addiction 2010; 105: 1117-1128.